Rotating Pazopanib and Everolimus to Avoid Resistance (ROPETAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01408004

Recruitment Status : Completed

First Posted : August 2, 2011

Last Update Posted : July 16, 2014

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Prof. dr. E.E. Voest, Netherlands Working Group on Immunotherapy of Oncology

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	April 2014
Actual Study Completion Date :	April 2014

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klumpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial. JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

To Top